Oren Miller, MD
Payments from drug & device makers
Across 66 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$291
- Bayer$142
- Dendreon Pharmaceuticals LLC$87
- E.r. Squibb & Sons, L.L.C.$75
- Antares Pharma, Inc.$64
- Accord Healthcare, Inc.$58
- plus $600 from 21 others
What the payments were for
- Food & beverage$1,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $291 |
| Bayer | 5 | $142 |
| Dendreon Pharmaceuticals LLC | 4 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Antares Pharma, Inc. | 4 | $64 |
| Accord Healthcare, Inc. | 3 | $58 |
| Pfizer | 2 | $54 |
| Olympus America Inc. | 2 | $48 |
| Merck | 2 | $46 |
| Novo Nordisk | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| AbbVie | 2 | $36 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Coloplast | 2 | $36 |
| Immunitybio, Inc. | 1 | $34 |
| Boston Scientific | 1 | $29 |
| Caris MPI, Inc. | 1 | $29 |
| Zyla Life Sciences, Inc. | 2 | $27 |
| Tolmar, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Telix Pharmaceuticals | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Palette Life Sciences, Inc. | 1 | $16 |
| SN Holdings, LLC | 5 | $0 |
| Urogpo LLC | 2 | $0 |
How this compares
$1,317 in reported general payments places this provider in the 35th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Solifenacin Succinate | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other urology in Tulsa
- Melanie KetchandjiTulsa$111K
- Curtis PowellTulsa$66K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Charles PritchardTulsa$23K
- Sean DoyleTulsa$17K
- Joshua VicenaTulsa$16K
- Wesley BrookoverTulsa$13K
- Thomas RashidTulsa$12K
- Dae KimTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.